LC-MS is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.
Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | No marketing authorization in major jurisdictions |
| Scheduling example | Prescription-only supply in some countries | Handled as an unlicensed medicine where restricted |
| Sports classification | Prohibited peptide | Appears on anti-doping prohibited lists |
| Reported presentation | Lyophilized vial | Nominal content varies between vendors |
| Detection approach | Liquid chromatography–tandem mass spectrometry | Used in anti-doping and forensic testing |
Verification of a purchased sample requires documentation linking a batch to a certificate of analysis, and that document should be read for the methods used rather than the headline purity figure. A single chromatographic percentage does not establish identity. Independent laboratories can perform identity and content assays, but no such test establishes that a product is suitable for human use. Claims about efficacy rest largely on small, early studies rather than on replicated controlled trials, and that gap remains open.
Identity testing for a cyclic peptide of this size usually relies on reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The mass spectrum confirms molecular weight, while the chromatographic trace indicates the proportion of related impurities. Tandem mass spectrometry can provide sequence-level information when fragmentation data are compared against a reference standard. Nuclear magnetic resonance is sometimes used to confirm the lactam bridge, although it requires more material and greater operator expertise than routine chromatographic methods.
Lyophilised peptide powder is comparatively stable when kept dry, cold and protected from light. Once dissolved, the molecule is exposed to hydrolysis, oxidation and microbial growth, and degradation accelerates at higher temperatures and in alkaline solution. Repeated freeze-thaw cycles concentrate solutes and promote aggregation. Handling guidance for research peptides commonly clusters around freezer temperatures for powder and short refrigerated use for reconstituted solutions, with pH control and sterile technique applied throughout.
Regulatory treatment varies by country. In the United States, melanotan-2 is not approved for any indication, and products marketed for human use fall outside the approved drug framework. Some other jurisdictions have placed it under prescription controls or listed it as a prohibited or restricted substance. Online listings frequently describe the material as a research chemical, a category that does not carry the same manufacturing and labelling requirements as approved medicines.
Solid peptide material is generally stable when kept cold and dry. Common practice is storage at -20 degrees Celsius or lower, with desiccant and protection from light. Repeated freeze-thaw cycles and exposure to moisture are associated with degradation, aggregation, or loss of material. Once dissolved, stability depends on solvent, concentration, and temperature, and solutions are usually treated as short-lived unless stability data support longer periods. Handling notes typically emphasise minimising time at ambient temperature.
Identity and purity are assessed with chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the target peptide from related impurities and degradation products, and the resulting retention time is compared against a reference standard. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass. Amino acid analysis or peptide mapping can provide additional sequence-level confirmation when required. Results are only as reliable as the reference materials used alongside them.
Sarcoidosis, amyloidosis, and Whipple's disease can also resemble RA. Hemochromatosis may cause hand joint arthritis. Acute rheumatic fever can be differentiated by a migratory pattern of joint involvement and evidence of antecedent streptococcal infection. Bacterial arthritis (such as by Streptococcus) is usually asymmetric, while RA usually involves both sides of the body symmetrically. Gonococcal arthritis (a bacterial arthritis) is also initially migratory and can involve tendons around the wrists and ankles. Sometimes arthritis is in an undifferentiated stage (i.e., none of the above criteria is positive), even if synovitis is witnessed and assessed with ultrasound imaging.
In 1968, after experiencing HD in his wife's family, Dr. Milton Wexler was inspired to start the Hereditary Disease Foundation (HDF), with the aim of curing genetic illnesses by coordinating and supporting research. The foundation and Wexler's daughter, Nancy Wexler, were key parts of the research team in Venezuela which discovered the HD gene. At roughly the same time as the HDF formed, Marjorie Guthrie helped to found the committee to Combat Huntington's Disease (now the Huntington's Disease Society of America), after her husband, folk singer-songwriter Woody Guthrie died from complications of HD. Since then, support and research organizations have formed in many countries around the world and have helped to increase public awareness of HD. A number of these collaborate in umbrella organizations, like the International Huntington Association and the European HD network. Many support organizations hold an annual HD awareness event, some of which have been endorsed by their respective governments. For example, 6 June is designated "National Huntington's Disease Awareness Day" by the US Senate. Many organizations exist to support and inform those affected by HD, including the Huntington's Disease Association in the UK. The largest funder of research is provided by the Cure Huntington's Disease Initiative Foundation (CHDI).
As of 2023, this is a list of supermarket chains, past and present, which operate or have branches in more than one country, whether under the parent corporation's name or another name. For supermarkets that are only in one country, see the breakdown by continent at the bottom of this page. Numbers are provided as the largest reported, and are largely inaccurate.
Nonviolence Speaks: Communicating against Repression, (Cresskill, NJ: Hampton Press, 2003). Martin, Brian. Technology for Nonviolent Struggle Archived 9 April 2009 at the Wayback Machine, (London: War Resisters' International, 2001). Martin, Brian with Lyn Carson. Random Selection in Politics, (Westport, CT: Praeger, 1999). Martin, Brian. The Whistleblower's Handbook: How to Be an Effective Resister, (Charlbury, UK: Jon Carpenter; Sydney: Envirobook, 1999). Updated and republished 2013 as Whistleblowing: a practical guide, Sparsnäs, Sweden: Irene Publishing. McCarthy, Robert J. "Blowing in the Wind: Answers for Federal Whistleblowers", 3 William & Mary Policy Review 184 (2012). Miethe, Terance D (1991). Whistleblowing at work: tough choices in exposing fraud, waste, and abuse on the job. Westview Press. ISBN 978-0-8133-3549-0. Rowe, Mary & Bendersky, Corinne, "Workplace Justice, Zero Tolerance and Zero Barriers: Getting People to Come Forward in Conflict Management Systems," in Negotiations and Change, From the Workplace to Society, Thomas Kochan and Richard Locke (eds), Cornell University Press, 2002 Wilkey, Robert N. Esq., "Federal Whistleblower Protection: A Means to Enforcing Maximum Hour Legislation for Medical Residents", William Mitchell Law Review, Vol. 30, Issue 1 (2003). Engineering Ethics concepts and cases by Charles E. Harris, Jr. – Michael S. Pritchard- Michael J. Rabins. IRS.gov Archived 4 August 2017 at the Wayback Machine, Whistleblower – Informant Award Whistleblower& Laws Australia – Global and Australian Laws: Steven Asnicar, 2019
Dimethylamine-corrinoid protein Co-methyltransferase (EC 2.1.1.249, mtbB (gene), dimethylamine methyltransferase) is an enzyme with systematic name dimethylamine:5-hydroxybenzimidazolylcobamide Co-methyltransferase. This enzyme catalyses the following chemical reaction
Sources: en.wikipedia.org
206Pb(48Ca,xn)254−xNo (x=1,2,3,4) The measurement of the 1-4n excitation functions for this reaction were reported in 2001 by Yuri Oganessian and co-workers at the FLNR. The 2n channel was further studied by the GSI to provide a spectroscopic determination of K-isomerism in 252No. A K-isomer with spin and parity 8− was detected with a half-life of 110 ms.
== Sources == Barceloux, Donald G., ed. (2008). Medical toxicology of natural substances: foods, fungi, medicinal herbs, plants, and venomous animals. John Wiley & Sons. ISBN 978-0-471-72761-3. Furman, Jon (2007). Timber rattlesnakes in Vermont and New York: biology, history, and the fate of an endangered species. UPNE. ISBN 978-1-58465-656-2. Klauber, Laurence M. & Greene, Harry W. (1997). Rattlesnakes: their habits, life histories, and influence on mankind. University of California Press. ISBN 978-0-520-21056-1. Rubio, Manny (1998). Rattlesnake: Portrait of a Predator. Smithsonian Books. ISBN 1-56098-808-8.
After his retreat, Liu established the "Ning-Ya-Kang Administrative Committee" in order to govern the areas still under his control. The Nationalist government would also follow suit in December 1934, creating a provincial establishment committee. Liu Wenhui was appointed by Nanjing as chairman of this committee: simultaneously, Liu Xiang was also named as the governor of Sichuan. It was officially formed in Ya'an in July 1935, and moved to Kangding in September 1936. Xikang was a poor region, isolated and rugged, and a reorganization by the Nationalists in 1936 would strip Liu of his rule over Ya'an and Xichang, which were turned over to Sichuan. The remaining lands were in such an impoverished state, with a population of barely 300,000 and a tax revenue of about 500,000 yuan, that Liu began to have trouble even securing food for the 24th Army. A desperate Liu Wenhui dispatched a mission to Nanjing to ask for his old territories back and for the central government to subsidize his budget; although Wang Jingwei was sympathetic to this idea, Chiang refused to grant him a bailout. Liu Xiang, the old rival of Liu Wenhui, likewise refused to return the regions he had just acquired, which stalled the plans to create an independent Xikang province. Respite for Liu would come in the form of the full-scale Japanese invasion of China, which forced the central government to move to Sichuan. More importantly, Liu Xiang would die from illness in 1938, clearing Sichuanese opposition to the Xikang project.
=== Institutional review boards (IRBs) === Approval by an Institutional Review Board (IRB), or Independent Ethics Committee (IEC), is necessary before all but the most informal research can begin. In commercial clinical trials, the study protocol is not approved by an IRB before the sponsor recruits sites to conduct the trial. However, the study protocol and procedures have been tailored to fit generic IRB submission requirements. In this case, and where there is no independent sponsor, each local site investigator submits the study protocol, the consent(s), the data collection forms, and supporting documentation to the local IRB. Universities and most hospitals have in-house IRBs. Other researchers (such as in walk-in clinics) use independent IRBs. The IRB scrutinizes the study both for medical safety and for protection of the patients involved in the study, before it allows the researcher to begin the study. It may require changes in study procedures or in the explanations given to the patient. A required yearly "continuing review" report from the investigator updates the IRB on the progress of the study and any new safety information related to the study.
==== Organ specialization ==== In multicellular eukaryotes, cells in different organs and tissues have different patterns of gene expression and therefore have different sets of enzymes (known as isozymes) available for metabolic reactions. This provides a mechanism for regulating the overall metabolism of the organism. For example, hexokinase, the first enzyme in the glycolysis pathway, has a specialized form called glucokinase expressed in the liver and pancreas that has a lower affinity for glucose yet is more sensitive to glucose concentration. This enzyme is involved in sensing blood sugar and regulating insulin production.
Sources: en.wikipedia.org
== Society and culture == Pantopon gave its name to the poem "Pantopon Rose" by the American writer William Burroughs and to a song with the same name by the Northern Ireland alternative metal band Therapy? on their 1994 album Troublegum. Pantopon also gave its name to the 1996 Mexican documentary Rosa Pantopon.
== Work == The new São Paulo Institute was built in a section of the city named Butantan, at the time a far-away place, near the Pinheiros river, a swampy, sparsely inhabited area. Under Vital Brazil, it soon became an energetic and exemplary research center in vaccines and sera of all kinds, which were produced locally for the prophylaxis and treatment of tetanus, diphtheria, yellow fever, smallpox and several zoonoses (diseases transmitted to humans by animals), such as the dreaded hydrophobia. The Institute came to be well known by his original name, the Butantan Institute, and is still active today. Vital Brazil was convinced since his early work at Butantan that envenomations (poisoning by accidents with venomous animals, such as snakes, scorpions, spiders and batrachia, then the cause of thousands of deaths in Brazil) could be fought with antisera, i.e., antibodies specifically produced for venoms which were proteins or long-chain peptides. A French immunologist, Albert Calmette (1863–1933) had demonstrated this for the first time in 1892, by developing a monovalent serum to treat bites by the Indian cobra (Naja tripudians).
== Structure == Free fatty acid receptor 3 is a member of the G protein-coupled receptor (GPCR) superfamily, characterized by its seven transmembrane alpha-helices. FFAR3 shares significant sequence similarity with FFAR2 but exhibits distinct structural features that influence its ligand specificity and signaling. The receptor's orthosteric binding pocket is formed by transmembrane helices 3, 4, and 5, with key conserved residues such as Arg-185 (5.39), Arg-255 (7.35), His-140 (4.56), and His-242 (6.55) contributing to the binding and recognition of short-chain fatty acids (SCFAs) like acetate, propionate, and butyrate. Notably, FFAR3's binding cavity is more hydrophilic compared to its close relative FFAR2, which affects its ligand interactions. The second extracellular loop is important in modulating ligand selectivity and receptor activation. Additionally, the presence of a His-45 (2.40) is predicted to coordinate allosteric modulators. The human FFAR3 and FFAR2 proteins consist of 346 and 330 amino acids, respectively, and share about a 40% amino acid sequence homology. The two FFARs have been found to form a heteromer complex (i.e., FFAR3 and FFAR2 bind to each other and are activated together by a SC-FA). When stimulated by a SC-FA, the cells expressing both FFAR3 and FFAR2 may form this heterodimer and thereby activate cell signaling pathways and mount responses that differ from those of cells expressing only one of these FFARs.
While genetic influences are important to understanding obesity, they cannot completely explain the dramatic increase seen within specific countries or globally. Though it is accepted that energy consumption in excess of energy expenditure leads to increases in body weight on an individual basis, the cause of the shifts in these two factors on the societal scale is much debated. There are a number of theories as to the cause but most believe it is a combination of various factors. The correlation between social class and BMI varies globally. Research in 1989 found that in developed countries women of a high social class were less likely to be obese. No significant differences were seen among men of different social classes. In the developing world, women, men, and children from high social classes had greater rates of obesity. In 2007 repeating the same research found the same relationships, but they were weaker. The decrease in strength of correlation was felt to be due to the effects of globalization. Among developed countries, levels of adult obesity, and percentage of teenage children who are overweight, are correlated with income inequality. A similar relationship is seen among US states: more adults, even in higher social classes, are obese in more unequal states. Many explanations have been put forth for associations between BMI and social class.
== Mistaken portrait == For two centuries, until the discovery of the error in 2005, books, paintings and articles had incorrectly shown a profile portrait of the obscure French politician Louis Legendre (1752–1797) as a portrait of the mathematician. The error arose from the fact that the sketch was labelled simply "Legendre" and appeared in a book along with contemporary mathematicians such as Lagrange. One of only two known portraits of Legendre, rediscovered in 2008, is found in the 1820 book Album de 73 portraits-charge aquarellés des membres de I'Institut, a book of caricatures of seventy-three members of the Institut de France in Paris by the French artist Julien-Léopold Boilly as shown below. The other portrait is from the book Le Panthéon scientifique de la tour Eiffel.
Sources: en.wikipedia.org
Only a small number of early-stage human studies have been reported, and most were limited in size and duration. No large late-stage program has established a general efficacy or safety profile. The evidence base is therefore thin compared with approved medicines.
The peptide is listed as prohibited in competitive sport, so laboratories develop detection methods and monitor for its presence. Its appearance in enforcement reports reflects that classification rather than any approved athletic use. Analytical work in this area focuses on identifying the molecule and its breakdown products in biological samples.
Chromatographic separation combined with mass spectrometry identifies the peptide and estimates its amount in a sample. Testing can confirm whether the expected molecule is present and at what concentration. It cannot establish how a product was manufactured or whether it meets any purity standard.
Regulatory treatment varies by country. In the United States, the European Union and Australia it is an unapproved drug and its sale is restricted, while some other jurisdictions list it as prescription-only or controlled. The applicable rules depend on the country of import.